Oegstgeest, Netherlands

Ferdinand Spies

This inventor holds 1 USPTO granted patent. Top assignee: Schwarz Pharma Ag. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ferdinand Spies

Introduction

Ferdinand Spies is a notable inventor based in Oegstgeest, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in enhancing the permeability of biological membranes. His work has implications for the development of more effective topical applications in medicine.

Latest Patents

Ferdinand Spies holds a patent for pharmaceutical compositions that contain 1-oleylazacycloheptan-2-one as an enhancing agent for transport across biological membranes. This invention focuses on pharmaceutical compositions designed for topical application, which include at least one physiologically active agent along with an effective amount of 1-oleylazacycloheptan-2-one. The aim is to improve the permeability of human or animal epithelial membranes, allowing for better absorption of the active ingredients.

Career Highlights

Ferdinand Spies is associated with Schwarz Pharma AG, where he has been involved in research and development efforts. His work has contributed to advancements in pharmaceutical formulations, particularly those aimed at improving drug delivery systems.

Collaborations

Ferdinand has collaborated with notable colleagues such as Henri Ernest Boddé and Johanna Aaltje Bouwstra. These collaborations have likely enriched his research and contributed to the success of his innovations.

Conclusion

Ferdinand Spies is a prominent figure in the pharmaceutical industry, recognized for his innovative work in enhancing drug delivery through improved membrane permeability. His contributions continue to influence the development of effective topical pharmaceutical compositions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…